Tumor cell clearance reimagined.
Our mission is to discover, translate, and deliver pioneering curative cell therapies that incorporate multiple forms of tumor clearance into single T cells.
Our technology aims to integrate anti-tumor capabilities of both the innate and adaptive immune systems into a single T cell.› Exploiting a Natural Immune Process
The CER platform
We are advancing a CER T-cell platform that potentially offers novel approaches for the treatment of both hematologic malignancies and solid tumors.› Therapeutic Potential of Our Platform
Join the quest
Our culture is mission-and innovation-driven towards bringing improved treatment options to patients. We are looking for talented and motivated individuals to join us in our quest.› Careers at CERo
A differentiated mechanism of action for solid tumors
Check out pre-clinical data on CER T cell activity in NSCLC presented at the Society of Immunotherapy of Cancer (SITC) annual meeting.› Read article
News and events
Feb 14, 2024Phoenix Biotech Acquisition Corp. and Cero Therapeutics Holdings, Inc. Announce Close of Business Combination
Jun 05, 2023CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
May 15, 2023Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation